Abstract
Early systemic hemodynamic adjustments to antihypertensive therapy with the cardioselective beta inhibitor, atenolol, were investigated in 12 hospitalized men, mean age 52 years, with uncomplicated mild-to-moderate essential hypertension. Twice daily measurements of cardiac output (CO) by CO2 rebreathing, blood pressure by cuff, and heart rate were performed in all subjects for 3 days before and 5 days after initiation of oral atenolol therapy (50 or 100 mg daily). Cardiac output by CO2 rebreathing was checked with dye dilution just before, and 4 hours and 4 days after the start of therapy. Plasma volume (radioiodinated albumin) was measured before therapy and on Day 5 of therapy. The CO results obtained with the two methods were not significantly different (r = 0.88, p less than 0.01, n = 12). A reduction in heart rate, 18 +/- 2 beats/min (mean +/- SE), occurred in all patients while taking atenolol. By 4 hours after the first dose of atenolol, CO fell from 5.49 +/- 0./30 to 4.24 +/- 0.21 liters/min (p less than 0.01), while the control mean arterial pressure (MAP) of 108 +/- 4 mm Hg was not significantly changed, 110 +/- 4 mm Hg. At 24 hours, CO returned near baseline (5.10 +/- 0.21 liters/min) but MAP was reduced (95 +/- 3 m...Continue Reading
References
Jun 1, 1977·The American Journal of Physiology·M A PfefferE D Frohlich
Oct 1, 1979·American Heart Journal·A MorgantiJ H Laragh
Jan 1, 1979·Cardiology·B N Prichard
May 1, 1979·Hypertension·T G ColemanW R Murphy
Apr 1, 1976·Circulation Research·D B AverillR Bajbus
Jan 1, 1975·Acta Pharmacologica Et Toxicologica·J StenbergL Werkö
Mar 1, 1977·American Heart Journal·J C PetrieJ Webster
Jun 12, 1979·European Journal of Clinical Pharmacology·S Rasmussen, K Rasmussen
Jun 1, 1978·Circulation Research·K H Berecek, D F Bohr
Feb 1, 1977·British Journal of Clinical Pharmacology·R Sannerstedt, H Wasir
Jul 1, 1973·British Heart Journal·B S LewisM S Gotsman
Jul 1, 1973·Circulation·J A FranciosaJ Conway
Sep 1, 1972·Proceedings of the Society for Experimental Biology and Medicine·E D FrohlichE D Jacobson
Feb 1, 1971·Clinical Science·M M Webb-PeploeR E Steiner
Dec 1, 1971·American Heart Journal·R C TaraziH P Dustan
Jul 1, 1972·Proceedings of the Society for Experimental Biology and Medicine·S JuliusR London
May 1, 1973·British Heart Journal·P A MajidS H Taylor
May 1, 1972·The American Journal of Cardiology·R C Tarazi, H P Dustan
May 1, 1971·Circulation Research·T G ColemanA C Guyton
Nov 1, 1968·The American Journal of Cardiology·J A NicoteroA P Shapiro
Sep 1, 1966·The American Journal of Cardiology·I BrickI C Roddie
Oct 1, 1966·British Journal of Pharmacology and Chemotherapy·S O Kayaalp, B K Kiran
Dec 1, 1961·The American Journal of Cardiology·J CONWAY, P LAUWERS
Citations
Aug 1, 1990·Cardiovascular Drugs and Therapy·P Omvik, P Lund-Johansen
May 21, 1983·Lancet·R C Bryant
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·M A van BaakJ F Smits
Oct 1, 1987·American Heart Journal·P Lund-Johansen
Apr 15, 1989·The American Journal of Cardiology·A G GillinD J Tiller
Jun 5, 1989·The American Journal of Cardiology·J A StromM P Poland
Jun 15, 1988·The American Journal of Cardiology·M R Weir, E Saunders
Jan 1, 1987·British Journal of Clinical Pharmacology·A H van den MeirackerM A Schalekamp
Apr 1, 1988·Journal of Clinical Pharmacology·C ReuseR Naeije
Apr 26, 1985·The American Journal of Cardiology·J N Cohn
Aug 1, 1988·American Heart Journal·J A Franciosa
Feb 17, 2001·Biopharmaceutics & Drug Disposition·S MostafaviR Foster
Oct 1, 1988·Circulation·A H van den MeirackerM A Schalekamp
Mar 1, 1984·Hypertension·P I Korner
Mar 1, 1984·Hypertension·H T ColferS Julius
Jan 1, 1985·Acta Medica Scandinavica. Supplementum·P Lund-JohansenH Haugland